Diffuse Large B-Cell Lymphoma Version 1.2016.
Diffuse large B-cell lymphomas (DLBCL) are now considered a heterogeneous group of distinct molecular subtypes (germinal center B-cell DLBCL, activated B-cell DLBCL, and primary mediastinal large B-cell lymphoma (PMBL) with varied natural history and response to therapy. In addition, a subset of patients with DLBCL have concurrent MYC and/or BCL2 gene rearrangements (double-hit lymphomas; DHL) and others have a dual expression of both MYC and BCL2 proteins (double-expressing DLBCL; DEL). The standard of care for the treatment of patients with PMBL, DHL, or DEL has not been established. Adequate immunophenotyping and molecular testing (in selected circumstances) are necessary for the accurate diagnosis of different subtypes of DLBCL. The NCCN Guidelines included in this issue, part of the NCCN Guidelines for non-Hodgkin's lymphomas, address the diagnosis and management of DLBCL and its subtypes.
Zelenetz, AD; Gordon, LI; Wierda, WG; Abramson, JS; Advani, RH; Andreadis, CB; Bartlett, N; Byrd, JC; Fayad, LE; Fisher, RI; Glenn, MJ; Habermann, TM; Lee Harris, N; Hernandez-Ilizaliturri, F; Hoppe, RT; Horwitz, SM; Kaminski, MS; Kelsey, CR; Kim, YH; Krivacic, S; LaCasce, AS; Lunning, M; Nademanee, A; Porcu, P; Press, O; Rabinovitch, R; Reddy, N; Reid, E; Roberts, K; Saad, AA; Sokol, L; Swinnen, LJ; Vose, JM; Yahalom, J; Zafar, N; Dwyer, M; Sundar, H
Volume / Issue
Start / End Page
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)